, sex and
暂无分享,去创建一个
K. Blennow | J. Molinuevo | R. Cacciaglia | C. Falcón | E. Rodriguez-Vieitez | J. Gispert | M. Milà-Alomà | G. Operto | G. Salvadó | M. Suárez-Calvet | I. Suridjan | Arianna Sala | M. Shekari | G. Kollmorgen | J. Domingo | Lundbeck Copenhagen | Gispert López | Henrik Zetterberg | Gwendlyn Kollmorgen
[1] W. M. van der Flier,et al. Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE ε4 genotype , 2020, Neurology.
[2] Mark E. Schmidt,et al. Multitracer model for staging cortical amyloid deposition using PET imaging , 2020, Neurology.
[3] Jesse A. Brown,et al. Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET , 2020, Science Translational Medicine.
[4] Muhammad Naveed Iqbal Qureshi,et al. Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β. , 2019, JAMA neurology.
[5] Philip S. Insel,et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease , 2019, EMBO molecular medicine.
[6] O. Hansson,et al. Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography. , 2019, JAMA neurology.
[7] M. Weiner,et al. APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points. , 2019, Journal of Alzheimer's disease : JAD.
[8] K. Blennow,et al. Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease , 2019, Molecular and Cellular Neuroscience.
[9] J. Leal,et al. The effect of ApoE ε4 on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: a FDG-PET study , 2019, NeuroImage: Clinical.
[10] K. Blennow,et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers , 2019, Alzheimer's Research & Therapy.
[11] Alan C. Evans,et al. Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease , 2019, bioRxiv.
[12] A. Fagan,et al. Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging , 2018, Alzheimer's & Dementia.
[13] C. Jack,et al. Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology , 2018, Alzheimer's & Dementia.
[14] N. Pedersen,et al. Differences Between Women and Men in Incidence Rates of Dementia and Alzheimer's Disease. , 2018, Journal of Alzheimer's disease : JAD.
[15] for the Alzheimer’s Disease Neuroimaging Initiative,et al. Sex differences in Alzheimer disease — the gateway to precision medicine , 2018, Nature Reviews Neurology.
[16] Yi Su,et al. Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE &egr;4 genotype , 2018, Brain : a journal of neurology.
[17] B. Borroni. Faculty of 1000 evaluation for PET imaging of tau deposition in the aging human brain. , 2018 .
[18] A. Ripka. Faculty of 1000 evaluation for Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging. , 2018 .
[19] Bin Zhang,et al. Amyloid-β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation , 2017, Nature Medicine.
[20] Daniel R. Schonhaut,et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease , 2017, Brain : a journal of neurology.
[21] Clifford R. Jack,et al. Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum , 2017, Cortex.
[22] J. Sepulcre,et al. In vivo staging of regional amyloid deposition , 2017, Neurology.
[23] Henrik Zetterberg,et al. Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity , 2017, Nature Communications.
[24] Philip S. Insel,et al. Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations , 2017, Alzheimer's Research & Therapy.
[25] T. Montine,et al. Cerebrospinal fluid biomarkers for Alzheimer's and vascular disease vary by age, gender, and APOE genotype in cognitively normal adults , 2017, Alzheimer's Research & Therapy.
[26] Pedro Rosa-Neto,et al. Synergistic interaction between amyloid and tau predicts the progression to dementia , 2017, Alzheimer's & Dementia.
[27] H. Vanderstichele,et al. Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition , 2017, Alzheimer's & Dementia.
[28] Christopher C Rowe,et al. Biochemically-defined pools of amyloid-&bgr; in sporadic Alzheimer’s disease: correlation with amyloid PET , 2017, Brain : a journal of neurology.
[29] M. Mintun,et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition , 2017, Brain : a journal of neurology.
[30] Ming-Rong Zhang,et al. Association between Aβ and tau accumulations and their influence on clinical features in aging and Alzheimer's disease spectrum brains: A [11C]PBB3-PET study , 2016, Alzheimer's & dementia.
[31] Johannes Kornhuber,et al. Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer’s Disease , 2016, Journal of Alzheimer's disease : JAD.
[32] Keith A. Johnson,et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.
[33] Hanna Cho,et al. Tau PET in Alzheimer disease and mild cognitive impairment , 2016, Neurology.
[34] Paul M. Thompson,et al. Age, APOE and sex: Triad of risk of Alzheimer’s disease , 2016, The Journal of Steroid Biochemistry and Molecular Biology.
[35] Daniel R. Schonhaut,et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. , 2016, Brain : a journal of neurology.
[36] A. Joshi,et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. , 2016, Brain : a journal of neurology.
[37] J. Molinuevo,et al. The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's disease , 2016, Alzheimer's & dementia.
[38] Daniel R. Schonhaut,et al. PET Imaging of Tau Deposition in the Aging Human Brain , 2016, Neuron.
[39] Jorge Sepulcre,et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.
[40] K. Blennow,et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease , 2015, Neurology.
[41] P. Albert,et al. Why is depression more prevalent in women? , 2015, Journal of psychiatry & neuroscience : JPN.
[42] E. Cadenas,et al. Perimenopause as a neurological transition state , 2015, Nature Reviews Endocrinology.
[43] C. Jack,et al. Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease. , 2015, JAMA neurology.
[44] Russell A. Poldrack,et al. Orthogonalization of Regressors in fMRI Models , 2015, PloS one.
[45] P. Snyder,et al. APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease , 2015, Neurobiology of Aging.
[46] Philip S. Insel,et al. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease. , 2015, Brain : a journal of neurology.
[47] Robert A. Koeppe,et al. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET , 2015, Alzheimer's & Dementia.
[48] J. Clarimón,et al. Cerebrospinal fluid β‐amyloid and phospho‐tau biomarker interactions affecting brain structure in preclinical Alzheimer disease , 2014, Annals of neurology.
[49] Philip S. Insel,et al. Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease , 2014, Annals of clinical and translational neurology.
[50] Rebecca A Betensky,et al. Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease , 2014, Neurology.
[51] Andre Altmann,et al. Sex modifies the APOE‐related risk of developing Alzheimer disease , 2014, Annals of neurology.
[52] S. Engelborghs,et al. Biobanking of CSF: international standardization to optimize biomarker development. , 2014, Clinical biochemistry.
[53] M. Mintun,et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid , 2013, Annals of neurology.
[54] M. Staufenbiel,et al. Changes in Amyloid-β and Tau in the Cerebrospinal Fluid of Transgenic Mice Overexpressing Amyloid Precursor Protein , 2013, Science Translational Medicine.
[55] Huaxi Xu,et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy , 2013, Nature Reviews Neurology.
[56] Henrik Zetterberg,et al. Fluid biomarkers in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.
[57] A. Dale,et al. Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau. , 2012, Archives of neurology.
[58] Denise C. Park,et al. &bgr;-Amyloid burden in healthy aging: Regional distribution and cognitive consequences , 2012, Neurology.
[59] C R Jack,et al. Spotlight on the January 24 Issue , 2012, Neurology.
[60] A. Drzezga,et al. Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid , 2009, Biological Psychiatry.
[61] K. Blennow,et al. The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease , 2009, Neurobiology of Aging.
[62] H. Soininen,et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. , 2009, Archives of neurology.
[63] Keith A. Johnson,et al. Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer's Disease , 2009, The Journal of Neuroscience.
[64] S. Rombouts,et al. Reduced resting-state brain activity in the "default network" in normal aging. , 2008, Cerebral cortex.
[65] R. Sperling,et al. Age-related memory impairment associated with loss of parietal deactivation but preserved hippocampal activation , 2008, Proceedings of the National Academy of Sciences.
[66] Benjamin J. Shannon,et al. Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory , 2005, The Journal of Neuroscience.
[67] L. Launer. The epidemiologic study of dementia: a life-long quest? , 2005, Neurobiology of Aging.
[68] L. Thal,et al. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease , 2004, Neurology.
[69] J. Wesson Ashford,et al. ApoE genotype accounts for the vast majority of AD risk and AD pathology , 2004, Neurobiology of Aging.
[70] K. Blennow,et al. CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study , 2003, Neurology.
[71] H. Braak,et al. Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.
[72] J. Haines,et al. Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .
[73] E M Wijsman,et al. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease , 1995, Neurology.
[74] S. Folstein,et al. “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .
[75] B. Hyman,et al. Synergy between amyloid-beta and tau in Alzheimer’s Disease , 2020 .
[76] S. O'Bryant,et al. Biomarkers of vascular risk, systemic inflammation, and microvascular pathology and neuropsychiatric symptoms in Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.
[77] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup , 2011 .
[78] D. Selkoe. Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.
[79] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.